我们的网站为什么显示成这样?

可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:

|本期目录/Table of Contents|

基于UPLC-MS/MS大鼠体内白术内酯Ⅰ、Ⅱ、Ⅲ的药代动力学参数研究(PDF)

《云南中医学院学报》[ISSN:1000-2723/CN:53-1048/R]

期数:
2020年03期
页码:
17-23
栏目:
实验研究
出版日期:
2020-11-15

文章信息/Info

Title:
In vivo Pharmacokinetic Parameters Study on Atractylenolide Ⅰ, Ⅱ, Ⅲin Rats by UPLC-MS/MS
作者:
许玲玲1姚兆敏1汪电雷1周媛媛1张敏1李晨辉1仰忠华2赵亚男13△
1. 安徽中医药大学药学院, 安徽 合肥 230012;2. 安徽仙寓山农业科技有限公司,安徽 黄山 245000;3. 皖南医学院第一附属医院弋矶山医院,安徽 芜湖 241001
Author(s):
XU Lingling1 YAO Zhaomin1 WANG Dianlei1 ZHOU Yuanyuan1 ZHANG Min1 LI Chenhui1 YANG Zhonghua2 ZHAO Yanan13
1. College of Pharmacy, Anhui University of Chinese Medicine, Hefei 230012, China;2. Anhui Xianyushan Agricultural Technology Co., Ltd., Huangshan 245000, China;3. Yijishan Hospital of Wannan Medical College, Wuhu 241001, China
关键词:
白术内酯I白术内酯II白术内酯IIIUPLC-MS/MS药代动力
Keywords:
atractylenolide I atractylenolide II atractylenolide III UPLC-MS pharmacokinetics
分类号:
R285
DOI:
10.19288/j.cnki.issn.1000-2723.2020.03.004
文献标识码:
A
摘要:
目的 通过UPLC-MS/MS法同时测定白术内酯I、II、III及其在大鼠体内的药代动力学参数研究。方法 以对乙酰氨基酚为内标,血浆样品前处理后进行UPLC-MS/MS分析。以0.05%磷酸水溶液-乙腈为流动相梯度洗脱,色谱柱Waters ACQUITY UPLC CSH C18柱(2.1 mm × 100 mm,1.7 μm),体积流量 0.2 mL/min,采用电喷雾离子化(ESI)源,正离子模式扫描,多反应监测模式(MRM)检测白术内酯I、II、III;采用 DAS 2.1药代动力学软件计算药代动力学参数。结果 白术内酯I、II、III的方法学验证良好,并成功应用于给药大鼠体内的药代动力学研究。结论 本方法可用于白术及其体内的药代动力学研究,为临床合理使用白术药材提供一定的参考价值。
Abstract:
Objective The simultaneous determination of atractylenolide I, II, III in rat plasma and its pharmacokinetic parameters study using UPLC-MS/MS. Methods The plasma samples were analyzed by UPLC-MS/MS after pretreatment with paracetamol as the internal standard. A reliable ESI source, positive ion mode scanning, and multiple reaction monitoring(MRM) method were developed for the simultaneous determination of atractylenolide I, II, III and chromatography was carried out on a Waters ACQUITY UPLC CSH C18(2.1 mm × 100 mm, 1.7 μm) using a gradient mobile phase consisted of 0.05% phosphoric acid water and acetonitrile at a flow rate of 0.2 mL/min. Calculations of the pharmacokinetic data were performed by using DAS 2.1 software. Results The methodology validation of atractylenolide I, II, III was good, and the validated method was successfully applied to the pharmacokinetic study after the rat oral administration of Atractylodes macrocephala Koidz. Decoction. Conclusion This method was available for pharmacokinetic parameters study after oral administration of Atractylodes macrocephala Koidz. and possibly provided a meaningful basis for clinical fair use of Atractylodes macrocephala Koidz.

参考文献/References

[1] 彭华胜,王德群. 白术道地药材的形成与变迁[J]. 中国中药杂志,2004(12):15-17.
[2] ZHU B,ZHANG Q L,HUA J W,et al. The traditional uses,phytochemistry,and pharmacology of Atractylodes macrocephala Koidz:A review[J]. J Ethnopharmacol,2018,226:143-167.
[3] HUANG H L,LIN T W,HUANG Y L,et al. Induction of apoptosis and differentiation by atractylenolide-1 isolated from Atractylodes macrocephala in human leukemia cells[J]. Bioorg Med Chem Lett,2016,26(8),1905-1909.
[4] DONG H,HE L,HUANG M,et al. Anti-inflammatory components isolated from Atractylodes macrocephala Koidz[J]. Nat Prod Res,2008,22(16):1418-1427.
[5] HOANG LE S,TRAN M H,LEE J S,et al. Inflammatory inhibitory activity of sesquiterpenoids from Atractylodes macrocephala rhizomes[J]. Chem Pharm Bull(Tokyo),2016,64(5):507-511.
[6] ZHANG N,LIU C,SUN T M,et al. Two new compounds from Atractylodes macrocephala with neuroprotective activity[J]. J Asian Nat Prod Res,2017,19(1):35-41.
[7] WANG C,DUAN H,HE L. Inhibitory effect of atractylenolide Ⅰ on angiogenesis in chronic inflammation in vivo and in vitro[J]. Eur J Pharmacol,2009,612(1-3):143-152.
[8] 郝延军,桑育黎,李宝林,等. 白术内酯Ⅰ及白术内酯Ⅲ对唾液淀粉酶活性的影响[J]. 时珍国医国药,2006(9):1617-1618.
[9] 张奕强,许实波,林永成. 白术内酯系列物的胃肠抑制作用[J]. 中药材,1999(12):636-640.
[10] LI Y,ZHANG Y,WANG Z,et al. Quantitative analysis of atractylenolide I in rat plasma by LC-MS/MS method and its application to pharmacokinetic study[J]. J Pharm Biomed Anal,2012,58:172-176.
[11] WANG R,WANG G,HAO H,et al. Quantitative determination of atractylenolide III in rat plasma by liquid chromatography electrospray ionization mass spectrometry[J]. J Chromatogr B Analyt Technol Biomed Life Sci,2006,831(1-2):36-41.
[12] Chen Q H,He H S,Li P,et al. Identification and quantification of atractylenolide I and atractylenolide III in Rhizoma Atractylodes macrocephala by liquid chromatography-ion trap mass spectrometry[J]. Biomed Chromatogr,2013,27(6):699-707.
[13] SHI Y Y,GUAN S H,TANG R N,et al. Simultaneous determination of atractylenolide II and atractylenolide III by liquid chromatographytandem mass spectrometry in rat plasma and its application in a pharmacokinetic study after oral administration of Atractylodes macrocephala Rhizoma extract[J]. Biomed Chromatogr,2012,26(11):1386-1392.
[14] 朱钊铭,李汉成,罗佳波. HPLC-MS法同时测定白术内酯Ⅰ、Ⅱ、Ⅲ及其在大鼠体内的药动学[J]. 中药药理与临床,2013,29(6):25-29.
[15] 姚兆敏,汪电雷,彭华胜,等. 白术UPLC指纹图谱模式识别及含量测定研究[J]. 中药新药与临床药理,2018,29(5):622-629.
[16] SONG H P,HOU X Q,LI R Y,et al. Atractylenolide I stimulates intestinal epithelial repair through polyamine-mediated Ca(2+)signaling pathway[J]. Phytomedicine,2017,28:27-35.
[17] LI W F,ZHI W B,LIU F,et al. Atractylenolide I restores HO-1 expression and inhibits Ox-LDL-induced VSMCs proliferation,migration and inflammatory responses in vitro[J]. Exp Cell Res,2017,353(1):26-34.
[18] LONG F,WANG T,JIA P,et al. Anti-Tumor Effects of Atractylenolide-I on Human Ovarian Cancer Cells[J]. Med Sci Monit,2017,23:571-579.
[19] WANG T,LONG F,ZHANG X,et al. Chemopreventive effects of atractylenolide II on mammary tumorigenesis via activating Nrf2-ARE pathway[J]. Oncotarget,2017,8(44):77500-77514.
[20] 张佳艺,闫梓乔,李 英,等. 大剂量白术临床应用现状[J]. 河南中医,2018,38(5):801-804.

备注/Memo

备注/Memo:
收稿日期: 2020 - 04- 02 基金项目: 2019安徽省重点研究与开发计划项目(201904a07020061) 第一作者简介: 许玲玲(1994-),女,在读硕士研究生,研究方向:药代动力学。 △通信作者: 赵亚男,E-mail:yananzhao888@126.com
更新日期/Last Update: 2020-11-15